Home > Zarnie Lwin, ESMO 2020 – Lenvatinib Plus Pembrolizumab in Advanced Solid Tumors: Initial results from LEAP-005
Immunotherapy

Zarnie Lwin, ESMO 2020 – Lenvatinib Plus Pembrolizumab in Advanced Solid Tumors: Initial results from LEAP-005

Published Online: October 7th 2020
Authors: Zarnie Lwin,

Dr Zarnie Lwin gives an overview of the interim findings of the LEAP-005 trial that were presented at the Virtual 2020 ESMO Congress, and the rationale for combining lenvatinib plus pembrolizumab for the treatment of solid tumours. The late-breaking abstract ‘LEAP-005: Phase 2 Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (Pts) With Previously Treated Advanced Solid Tumors’ (LBA41) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.

Questions

  1. What is the rationale for the combined use of lenvatinib plus pembrolizumab in the treatment of advanced solid tumours? (0:17)
  2. Could you tell us a little about the aims and design of the LEAP-005 study? (1:30)
  3. What were the interim findings, and have the primary endpoints of objective response rate, safety and tolerability been met so far? (2:58)
  4. What are the remaining gaps in our knowledge and what is planned for the remainder of the study? (4:16)

Speaker Disclosure: Zarnie Lwin serves on the scientific advisory committee for LEAP 005 which is sponsored by Merck Sharpe and Dohme and has received honoraria for consulting, advisory roles or travel sponsorship by AbbVie, AstraZeneca, BMS, Roche and Merck.

Support: Interview and filming supported by Touch Medical Media Ltd. The LEAP-005 study was funded by Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Filmed in coverage of the Virtual 2020 ESMO Congress.

Share this Video
Related Videos In Immunotherapy
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar